Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02329847
Title Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Janssen Research & Development, LLC

chronic lymphocytic leukemia/small lymphocytic lymphoma

non-Hodgkin lymphoma


Ibrutinib + Nivolumab

Age Groups: adult
Covered Countries USA | ESP

No variant requirements are available.